What is the translation of " SUBCUTANEOUS FORMULATION " in Swedish?

• subkutan formulering

Examples of using Subcutaneous formulation in English and their translations into Swedish

The bioavailability for the subcutaneous formulation was 79.
Biotillgängligheten för den subkutana formuleringen var 79.

MabThera subcutaneous formulation was given at a fixed dose of 1400 mg.
MabThera subkutan formulering gavs i en fast dos på 1400 mg.

Adverse reactions reported in MabThera subcutaneous formulation usage.
Biverkningar som rapporterats för MabThera subkutan formulering.

Herceptin subcutaneous formulation in administration system is ready to use.
Herceptin subkutan formulering i administreringssats är färdig att använda.

Description of selected adverse reactions with the subcutaneous formulation.
Beskrivning av vissa biverkningar med subkutan formulering.

Herceptin subcutaneous formulation was locally
Herceptin subkutan formulering tolererades väl

Administration-related reactions(ARRs) are known to occur with Herceptin subcutaneous formulation.
Det är känt att administrationsrelaterade reaktioner förekommer med Herceptin subkutan formulering.

Absorption parameters of subcutaneous formulation, decreased with increasing BMI.
Absorptionsparametrar för subkutan formulering minskade med en ökande BMI.

Switching treatment between Herceptin intravenous and Herceptin subcutaneous formulation and vice versa.
Byte av behandling mellan Herceptin intravenös och Herceptin subkutan formulering och vice versa.

MabThera 1400 mg subcutaneous formulation should be administered as subcutaneous injection only, over approximately 5 minutes.
MabThera 1400 mg subkutan formulering ska endast ges som subkutan injektion, under ca 5 minuter.

For instructions on use and handling of Herceptin subcutaneous formulation refer to section 6.6.
För instruktioner gällande användning och hantering av Herceptin subkutan formulering se avsnitt 6.6.

MabThera subcutaneous formulation is not intended for intravenous administration
MabThera subkutan formulering är inte avsett för intravenös administrering

Clinical experience of MabThera subcutaneous formulation in Non-Hodgkin's lymphoma.
Klinisk erfarenhet av MabThera subkutan formulering hos patienter med non-Hodgkins lymfom.

Some adverse events/ reactions were reported with a higher frequency for the subcutaneous formulation.
Vissa biverkningar(händelser/reaktioner) rapporterades i en högre frekvens för den subkutana formuleringen.

The dose of 1600 mg of MabThera subcutaneous formulation was selected for the Part 2 of the study.
Dosen 1600 mg för MabThera subkutan formulering valdes för den andra delen av studien.

Local cutaneous reactions including injection site reactions were very common in patients receiving MabThera subcutaneous formulation.
Lokala hudreaktioner, inklusive reaktioner vid injektionsstället, var mycket vanligt hos patienter som fick MabThera subkutan formulering.

Clinical experience of MabThera subcutaneous formulation in chronic lymphocytic leukaemia.
Klinisk erfarenhet av MabThera subkutan formulering hos patienter med kronisk lymfatisk leukemi.

Administration related reactions have been observed in up to 50% of patients treated with MabThera subcutaneous formulation in clinical trials.
Administrationsrelaterade reaktioner har observerats hos upp till 50% av patienterna som behandlats med MabThera subkutan formulering i kliniska studier.

The interval between consecutive Herceptin subcutaneous formulation administrations should not be less than three weeks.
Behandlingsintervallet tills påföljande administrering av Herceptin subkutan formulering bör inte understiga tre veckor.

an antihistamine should always be administered before each dose of MabThera subcutaneous formulation.
ett analgetikum/ antipyretikum och ett antihistamin bör alltid administreras före varje dos av MabThera subkutan formulering.

Therefore, the switch to MabThera subcutaneous formulation can only occur at the second
Byte till MabThera subkutan formulering kan därför endast ske inför den andra

following administration of MabThera subcutaneous formulation.
efter administrering av MabThera subkutan formulering.

Of patients treated with Herceptin subcutaneous formulation developed antibodies against the excipient hyaluronidase rHuPH20.
Av patienterna som behandlades med Herceptin subkutan formulering utvecklade antikroppar mot hjälpämnet hyaluronidas rHuPH20.

Herceptin subcutaneous formulation contains recombinant human hyaluronidase(rHuPH20),
Herceptin subkutan formulering innehåller rekombinant humant hyaluronidas(rHuPH20)

The comparison of predicted median Cmax data for MabThera subcutaneous formulation and intravenous formulation are summarized in Table 7.
Jämförelsen av data för det predikterade medianvärdet för Cmax för MabThera subkutan formulering och intravenös formulering sammanfattas i tabell 7.

The recommended dose of MabThera subcutaneous formulation used for adult patients is a subcutaneous injection at a fixed dose of 1400 mg irrespective of the patient's body surface area.
Den rekommenderade dosen av MabThera subkutan formulering som används för vuxna patienter är en subkutan injektion med en fast dos på 1400 mg oavsett patientens kroppsyta.

All of the severe ARRs with the Herceptin subcutaneous formulation occurred during concurrent administration with chemotherapy.
Alla svåra administrationsrelaterade reaktioner med Herceptin subkutan formulering inträffade vid samtidig administrering av kemoterapi.

The median Tmax in the MabThera subcutaneous formulation was approximately 3 days as compared to the Tmax occuring at
Medianvärdet för Tmax vid MabThera subkutan formulering var ca 3 dagar jämfört med Tmax för den intravenösa formuleringen

For instructions on use and handling of Herceptin subcutaneous formulation, refer to section 6.6 of the SmPC,
För instruktioner gällande användning och hantering av Herceptin subkutan formulering se avsnitt 6.6 i produktresumén

Herceptin subcutaneous formulation was administered in the neoadjuvant/adjuvant setting in patients with early breast cancer.
administrerades Herceptin subkutan formulering som neoadjuvant/ adjuvant behandling hos patienter med tidig bröstcancer.

How to use "subcutaneous formulation" in a sentence

The levels of the subcutaneous formulation allows for crier testing.

Benlysta subcutaneous formulation is currently not approved in the European Union.

A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.

The subcutaneous formulation of Herceptin uses technology developed by Halozyme Therapeutics, Inc.

Scientific session : Subcutaneous formulation of furosemide: endless opportunities for an old drug.

We, along with other colleagues, are looking at a subcutaneous formulation of daratumumab.

It is not recommended to use the subcutaneous formulation of ORENCIA in children.

Tocilizumab is administered IV monthly but recently a subcutaneous formulation has been launched.

Belimumab subcutaneous formulation is currently not approved for use anywhere in the world.

Some patients may prefer a subcutaneous formulation since therapy can be administered at home.